Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
NCT06180499
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Hematological Malignancies
Regulatory T Cell Depletion
Relapse
Interventions
DRUG:
T-reg depleted DLI
Sponsor
Assistance Publique - Hôpitaux de Paris